Effectiveness and Safety of Romiplostim Among Patients with Newly Diagnosed, Persistent and Chronic Immune Thrombocytopenia in European Clinical Practice
mediaposted on 2021-04-15, 12:26 authored by Adis journals on behalf of, Sara J. Snell Taylor, Carrie M. Nielson, Alexander Breskin, Bradley Saul, Ying Yu, Naufil Alam, Melissa Eisen, Jane Hippenmeyer, Ann Janssens, Tomas Kozak, Helen A Papadaki, Dominik Selleslag, Jean-Francois Viallard, Clemens Feistritzer, Georgia Kaiafa, Mike Kelsh, Karynsa Kilpatrick, M. Alan Brookhart, Leah J. McGrath
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.